Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 9/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523428 | 1.00 | UTS2R (0.54) | UTS2RCTSKTAS1R3TAS1R1CTSS | |
| SCHEMBL14342616 | 1.00 | UTS2R (0.54) | UTS2RCTSKTAS1R3TAS1R1CTSS | |
| SCHEMBL4252396 | 0.91 | UTS2R (0.45) | UTS2RCTSKCTSSCTSBTRPV4 | |
| SCHEMBL14342662 | 0.90 | UTS2R (0.44) | UTS2RCTSKCTSSCTSB | |
| SCHEMBL5518167 | 0.90 | UTS2R (0.44) | UTS2RCTSKCTSSCTSB | |
| SCHEMBL4075170 | 0.90 | UTS2R (0.44) | UTS2RCTSKCTSSCTSB | |
| SCHEMBL4076026 | 0.90 | UTS2R (0.53) | UTS2RCTSKTAS1R3TAS1R1CTSS | |
| SCHEMBL4074839 | 0.89 | UTS2R (0.43) | UTS2RCTSKCTSSCTSBCTSL | |
| SCHEMBL14342666 | 0.89 | UTS2R (0.43) | UTS2RCTSKCTSSCTSBCTSL | |
| SCHEMBL8270899 | 0.89 | CTSK (0.58) | UTS2RCTSKTAS1R3TAS1R1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | claimed |
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | UTS2R 315/4885CTSK 2064/4885TAS1R3 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.